Get in touch with us.

We are the only organization focused building an influence network to drive change.

No. The resources and attention dedicated to longevity today are a tiny fraction of what they could be, especially given the seriousness of the problem of aging. Current initiatives, often even according to their creators, are not going to yield major lifespan gains.

Special Economic Zones and Charter Cities are important for longevity, but they are also vulnerable to the arbitrary decisions of the greater jurisdictions in which they operate. Most such jurisdictions are limited in capital attractiveness, and maturity, limiting their effectiveness.

Absolutely, we intend to spread Vitalism in every corner of the world.

‍

We support lobbying as one of multiple measures. One challenge is that without a core and consistent voting constituency as well as concomitant economic interests and systematic coordination with for profit and non-profit stakeholders, any political support may be ephemeral. Additionally, lobbying efforts are often only able to reach a small group of leaders and cannot effect deep and wide systemic change.

No. Longevity only gets less than 1% of biotech venture capital despite aging being the primary driver of healthcare costs. For a problem of this magnitude, humanity should be dedicating at least 1% of global GDP (~$1 Trillion), which is around 1000x more than what is being invested in fighting aging today. Despite spending around $11B in the last 25 years on various longevity companies, we yet to see ameaningful inflection in overall funding and attention.